Skip to content

Efficacy of Transcutaneous Electrical Acupoint Stimulation for Taste Disorders in Head and Neck Cancer Patients Receiving Radiotherapy: A Multicenter Randomized Controlled Trial

Optimization of percutaneous acupoint electrical stimulation to improve taste disorders in patients with oral cancer after radiotherapy and a multicenter randomized controlled study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101613
Enrollment
Unknown
Registered
2025-04-27
Start date
2025-05-05
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

experimental group:Transcutaneous Electrical Acupoint Stimulation
Control group:For sham transcutaneous electrical acupoint stimulation: The instruments, procedures, frequencies, durations, pulse frequencies and widths set for the intervention are all the same. Howe

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age over 18 years old; 2. Patients diagnosed with head and neck cancer by the hospital's pathology department and undergoing radiotherapy; 3. Patients are undergoing their first radiotherapy; 4. Karnofsky (KPS) functional status score >= 50 points, and without severe organic damage to the heart, liver, brain, kidney, etc.; 5. Expected survival period >= 6 months; 6. Patients voluntarily participate, conscious, able to communicate normally, and without mental illness or cognitive impairment.

Exclusion criteria

Exclusion criteria: 1. Patients with complete loss of taste sensation; 2. Patients with taste disorders unrelated to head and neck tumors (such as taste disorders caused by central nervous system diseases, influenza, etc.); 3. Patients with total tongue resection or resection of the lingual nerve; 4. Patients using drugs and devices that affect taste function during radiotherapy (such as the radiation protection agent amitriptyline, the drug piracetam that increases saliva secretion, zinc preparations, oral supports or bite blocks, etc.); 5. Patients known or suspected to be allergic to the test-related materials or have corresponding contraindications; 6. Patients with damaged or swollen skin at the selected acupoints.

Design outcomes

Primary

MeasureTime frame
Objective taste score;

Secondary

MeasureTime frame
Subjective taste evaluation;The situation of appetite;Quality of life;

Countries

China

Contacts

Public ContactLili Hou

The Nursing Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

pisces_liz@163.com+86 138 1603 3620

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026